![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » SOLVAY OBTAINS MARKET AUTHORISATION IN 28 EUROPEAN COUNTRIES FOR DUODOPA
SOLVAY OBTAINS MARKET AUTHORISATION IN 28 EUROPEAN COUNTRIES FOR DUODOPA
November 28, 2005
Solvay, the Belgian chemicals and pharmaceuticals group, said it has obtained market authorization for Duodopa, the product for treating advanced Parkinson's disease, in 28 European countries. Duodopa now has a registration in Sweden, Austria, Germany, Denmark, Spain, Finland, France, The Netherlands, Norway, Portugal, Belgium, Greece, Ireland, Italy, United Kingdom, Cyprus, Czech Republic, Estonia, Hungary, Iceland, Liechtenstein, Lithuania, Luxembourg, Latvia, Malta, Poland, Slovenia, and Slovakia.
Forbes (http://www.forbes.com/business/feeds/afx/2005/11/28/afx2354803.html)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct